Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic Innovation

The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.